Kagoshima University · Joint Research Center for Human Retrovirus Studies · 准教授

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Koze Hinako, Sudoh Masayuki, Onitsuka Satoaki, Okamura Hiroaki, Ishikawa Takeshi, Tani Fumito, Miyata-Yabuki Yukako, Shirouzu Mikako, Baba Masanori, Okamoto Mika, Hamada Toshiyuki2025 · 記述言語： 英語 出版者・発行元： シュプリンガー・ジャパン(株)
• Baba M., Okamoto M., Toyama M., Sakakibara N., Shimojima M., Saijo M., Niwa T., Yagi Y. . Amodiaquine derivatives as inhibitors of severe fever with thrombocytopenia syndrome virus (SFTSV) rep2022 · 記述言語： 日本語 出版者・発行元： Antiviral Research Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral infection caused by a bandavirus in the family of Phenuiviridae, commonly known as SFTS virus (SFTSV). We have previously isolated SFTSV from blood samples of SFTS patients and established an antiviral assay system to identify selective inhibitors of SFTSV in vitro. Using the assay system, the antimalarial agent amodiaquine was identified as a selective inhibitor of SFTSV replication. However, due to its insufficient antiviral activity, 98 amodiaquine derivatives were newly synthesized and examined for their anti-SFTSV activity. Among the derivatives, some compounds showed selective inhibitory effect on SFTSV replication in vitro. The 50% effective concentration (EC50) and cytotoxic concentration (CC50) of the most active compound (C-90) were 2.6 ± 0.6 and >50 μM, respectively. This EC50 value was comparable to or slightly better than that of favipiravir (4.1 ± 0.6 μM). On the other hand, pharmacokinetic studies in vivo revealed that C-90 was poor in its oral bioavailability in mice. Therefore, we further designed and synthesized derivatives and obtained 2 compounds with selective anti-SFTSV activity in vitro and improved pharmacokinetics in vivo. DOI： 10.1016/j.antiviral.2022.105479 Scopus PubMed
• Okamoto M, Toyama M, Baba M. . The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro . Antiviral Research182 1049022020 · 担当区分： 筆頭著者 記述言語： 英語 掲載種別： 研究論文（学術雑誌） 出版者・発行元： Antiviral Research DOI： 10.1016/j.antiviral.2020.104902 Scopus PubMed
• Kajiya T., Sawayama H., Arima E., Okamoto M., Baba M., Toyama M., Okuya K., Ozawa M., Atsuchi N., Nishi J., Suda Y. . Novel RT-PCR Using Sugar Chain-Immobilized Gold-Nanoparticles Correlates P2020 · 記述言語： 日本語 出版者・発行元： Viruses Background: The transmissible capacity and toxicity of SARS-CoV-2 variants are continually changing. We report here the follow-up study of hospitalized COVID-19 patients from 2020 to 2022. It is known that the PCR diagnosis for hospitalized patients sometimes causes confusion because of the incompatibility between their diagnosis and symptoms. We applied our sugar chain-immobilized gold-nanoparticles for the extraction and partial purification of RNA from specimens for quantitative RT-PCR assay and evaluated whether the results correlate with patients' symptoms. Methods and Results: Saliva specimens were taken from hospitalized patients with mild or moderate symptoms every early morning. At the time of RT-PCR diagnosis, two methods for the extraction and partial purification of RNA from the specimen were performed: a commonly used Boom (Qiagen) method and our original sugar chain-immobilized gold nanoparticle (SGNP) method. For symptoms, body temperature and oxygen saturation (SpO2) of patients were monitored every 4 h. Conclusions: It was clear that patients infected with the Delta variant needed more time to recover than those with the Omicron variant, and that the SGNP method showed more realistic correlation with the symptoms of patients compared with the common Qiagen method. DOI： 10.3390/v14112577 Scopus PubMed

• 大学院医学修士講義「感染と生体防御」2021 · 2021年7月 - 現在 機関名： 鹿児島大学
• NHKスペシャル パンデミック 激動の世界（６）「“科学立国” 再生への道」2020 · 日本放送協会 NHKスペシャル 2020年12月
• 大学院医学修士講義「分子薬理学・創薬科学」2019 · 2019年1月 - 現在 機関名： 鹿児島大学
• エイズ根治療法を目指したHIV-1慢性感染細胞を選択的に殺傷する薬剤の開発2017 · 担当区分： 研究代表者

• Official profile